Jessica Hergert | Authors

Articles

Atezolizumab Survival Advantage Continues To Be Seen in Frontline PD-L1–High NSCLC

January 31, 2021

Multiple key efficacy end points continue to favor atezolizumab versus chemotherapy for patients with PD-L1–high, wild-type nonsquamous or squamous non–small cell lung cancer in the first line, according to a phase 3 trial follow-up.

Relapsed/Refractory Metastatic NSCLC Tumors Respond to Datopotamab Deruxtecan in Early Trial

January 31, 2021

The investigational TROP-2–directed antibody-drug conjugate datopotamab deruxtecan will move forward in the treatment of relapsed/refractory non–small cell lung cancer, according to results from the 2020 World Conference on Lung Cancer Singapore.

Phase 3 Trial Finds Adjuvant Neratinib Shows Promise for Early-Stage HER2+ Breast Cancer

December 11, 2020

Fewer deaths and improved cumulative incidence of central nervous system recurrences were shown at 8 years of follow-up with adjuvant neratinib (Nerlynx) compared with placebo in patients with early-stage HER2-positive breast cancer following trastuzumab (Herceptin)-based therapy.

Novel ADC Shows Clinical Activity in MCL and DLBCL, First-in-Human Trial Finds

December 06, 2020

A novel ROR1-targeted antibody-drug conjugate, VLS-101, demonstrated encouraging clinical efficacy, consistent pharmacokinetics, and a favorable safety profile in patients with heavily pretreated mantle cell lymphoma and diffuse large B-cell lymphoma.

Significant Racial, Ethnic Related Socioeconomic Disparities Influence Survival in AML

December 06, 2020

Census tract socioeconomic status information demonstrated significant disparities between survival outcomes of non-Hispanic white, non-Hispanic black, and Hispanic patients with acute myeloid leukemia AML in the Chicago metropolitan area.

Phase 3 CheckMate-649 Study Sees Promising Survival Benefit with Frontline Nivolumab, Chemo Combo

September 22, 2020

The combination of nivolumab (Opdivo) and chemotherapy led to a statistically significant survival benefit among previously untreated patients with PD-L1–positive advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.